UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:UTI - US9139151040 - Common Stock
26.52 USD
-1.14 (-4.12%)
26.52 USD
0 (0%)
UTI gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 76 industry peers in the Diversified Consumer Services industry. UTI scores excellent on profitability, but there are some minor concerns on its financial health. UTI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year UTI was profitable.
- UTI had a positive operating cash flow in the past year.
- Each year in the past 5 years UTI has been profitable.
- Each year in the past 5 years UTI had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of UTI (7.63%) is better than 72.37% of its industry peers.
- Looking at the Return On Equity, with a value of 19.21%, UTI belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 10.46%, UTI belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for UTI is below the industry average of 10.30%.
- The last Return On Invested Capital (10.46%) for UTI is above the 3 year average (7.27%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.63% | ||
| ROE | 19.21% | ||
| ROIC | 10.46% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- With a decent Profit Margin value of 7.54%, UTI is doing good in the industry, outperforming 67.11% of the companies in the same industry.
- UTI's Profit Margin has improved in the last couple of years.
- UTI has a Operating Margin of 9.99%. This is in the better half of the industry: UTI outperforms 65.79% of its industry peers.
- In the last couple of years the Operating Margin of UTI has grown nicely.
- UTI has a Gross Margin (49.68%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of UTI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.99% | ||
| PM (TTM) | 7.54% | ||
| GM | 49.68% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTI is still creating some value.
- UTI has more shares outstanding than it did 1 year ago.
- UTI has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, UTI has an improved debt to assets ratio.
2.2 Solvency
- UTI has an Altman-Z score of 3.28. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.28, UTI is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
- UTI has a debt to FCF ratio of 1.57. This is a very positive value and a sign of high solvency as it would only need 1.57 years to pay back of all of its debts.
- The Debt to FCF ratio of UTI (1.57) is better than 84.21% of its industry peers.
- A Debt/Equity ratio of 0.26 indicates that UTI is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.26, UTI is in line with its industry, outperforming 53.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.57 | ||
| Altman-Z | 3.28 |
ROIC/WACC1.23
WACC8.51%
2.3 Liquidity
- UTI has a Current Ratio of 1.07. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI has a Current ratio of 1.07. This is comparable to the rest of the industry: UTI outperforms 47.37% of its industry peers.
- UTI has a Quick Ratio of 1.07. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.07, UTI perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
- UTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.05%, which is quite impressive.
- Measured over the past years, UTI shows a very strong growth in Earnings Per Share. The EPS has been growing by 65.96% on average per year.
- The Revenue has grown by 14.05% in the past year. This is quite good.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)54.05%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%0%
Revenue 1Y (TTM)14.05%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%13.28%
3.2 Future
- The Earnings Per Share is expected to decrease by -11.51% on average over the next years. This is quite bad
- The Revenue is expected to grow by 8.99% on average over the next years. This is quite good.
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.23%
Revenue Next 2Y8.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 23.26, which indicates a rather expensive current valuation of UTI.
- UTI's Price/Earnings ratio is in line with the industry average.
- UTI's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.30.
- A Price/Forward Earnings ratio of 34.05 indicates a quite expensive valuation of UTI.
- The rest of the industry has a similar Price/Forward Earnings ratio as UTI.
- UTI is valuated rather expensively when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.26 | ||
| Fwd PE | 34.05 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UTI indicates a somewhat cheap valuation: UTI is cheaper than 63.16% of the companies listed in the same industry.
- UTI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. UTI is cheaper than 64.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.08 | ||
| EV/EBITDA | 11.33 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
- A cheap valuation may be justified as UTI's earnings are expected to decrease with -11.51% in the coming years.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y-11.51%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
26.52
-1.14 (-4.12%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)11-19 2025-11-19/amc
Earnings (Next)02-03 2026-02-03
Inst Owners97.52%
Inst Owner Change3.35%
Ins Owners2.78%
Ins Owner Change5.07%
Market Cap1.44B
Revenue(TTM)835.62M
Net Income(TTM)63.02M
Analysts81.82
Price Target38.18 (43.97%)
Short Float %4.93%
Short Ratio3.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.09%
Min EPS beat(2)28.91%
Max EPS beat(2)69.26%
EPS beat(4)4
Avg EPS beat(4)73.64%
Min EPS beat(4)28.91%
Max EPS beat(4)123.12%
EPS beat(8)7
Avg EPS beat(8)75.72%
EPS beat(12)10
Avg EPS beat(12)77.26%
EPS beat(16)14
Avg EPS beat(16)214.91%
Revenue beat(2)2
Avg Revenue beat(2)0.81%
Min Revenue beat(2)0.47%
Max Revenue beat(2)1.15%
Revenue beat(4)4
Avg Revenue beat(4)2.24%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.25%
Revenue beat(12)12
Avg Revenue beat(12)3.17%
Revenue beat(16)15
Avg Revenue beat(16)3.41%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.61%
EPS NQ rev (3m)-43.81%
EPS NY rev (1m)-2.53%
EPS NY rev (3m)-21.31%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-0.64%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)0.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.26 | ||
| Fwd PE | 34.05 | ||
| P/S | 1.73 | ||
| P/FCF | 26.08 | ||
| P/OCF | 14.83 | ||
| P/B | 4.4 | ||
| P/tB | 5.11 | ||
| EV/EBITDA | 11.33 |
EPS(TTM)1.14
EY4.3%
EPS(NY)0.78
Fwd EY2.94%
FCF(TTM)1.02
FCFY3.83%
OCF(TTM)1.79
OCFY6.74%
SpS15.35
BVpS6.03
TBVpS5.19
PEG (NY)N/A
PEG (5Y)0.35
Graham Number12.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.63% | ||
| ROE | 19.21% | ||
| ROCE | 13.99% | ||
| ROIC | 10.46% | ||
| ROICexc | 14.6% | ||
| ROICexgc | 16.35% | ||
| OM | 9.99% | ||
| PM (TTM) | 7.54% | ||
| GM | 49.68% | ||
| FCFM | 6.62% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score6
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.57 | ||
| Debt/EBITDA | 0.72 | ||
| Cap/Depr | 127.37% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 14.13 | ||
| Cash Conversion | 83.6% | ||
| Profit Quality | 87.84% | ||
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 3.28 |
F-Score6
WACC8.51%
ROIC/WACC1.23
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.05%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%0%
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.05%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%13.28%
Revenue Next Year9.23%
Revenue Next 2Y8.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.41%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.14%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y13.31%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 3 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
Can you provide the financial health for UTI stock?
The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 6 / 10.
What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.68% in the next year.